Compare ICICI Bank Limited Common Stock (IBN) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ICICI Bank Limited Common Stock vs Repligen Corporation Common Stock — how do they compare? ICICI Bank Limited Common Stock trades at $28.82 (market cap $101.96B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: ICICI Bank Limited Common Stock is far larger — about 9.2× Repligen Corporation Common Stock's market cap, and ICICI Bank Limited Common Stock pays a 0.88% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold ICICI Bank Limited Common Stock for 6 Days and Repligen Corporation Common Stock for 0 Days on average.
| IBN | RGEN | |
|---|---|---|
Market Cap | $101.96B | $11.14B |
Volume | 5,301,480 | 1,259,263 |
Sector | Financials | Health |
52-Week High | $32.94 | $194.57 |
52-Week Low | $25.20 | $102.87 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $9.90T | $11.02B |
Dividend Yield | 0.88% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IBN trades at $28.54, up 1.75% today, showing strong momentum with recent earnings beats in Q1 and Q2 2026. The stock maintains robust fundamentals including a 24.8% net income margin and 15.8% ROE, supported by $2.05T revenue in 2025. Technical indicators show bearish signals despite unanimous analyst buy ratings, with RSI suggesting potential overbought conditions near current levels.
The outlook remains positive given strong profitability metrics and analyst consensus, but technical weakness and high valuation multiples (P/E 17.85, P/S 4.43) present near-term risks. Investors should monitor Q3 2026 earnings results against expectations of $0.40 EPS for continued fundamental confirmation.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ICICI Bank Limited Common Stock
ICICI Bank is an Indian financial services company providing banking, lending, cards, insurance, and investment products. It serves retail, business, and corporate customers.
Read more on IBN →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
